Results from the largest ever individually randomised influenza vaccine effectiveness study

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in to view the resources

About the speaker

Professor Tor Biering-Sorensen

Gentofte University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail

Opening remarks

Professor M. Volpe (Rome, IT)

Presentation thumbnail

A dose to support independence: evidence journey of high-dose influenza vaccine for older adults

Doctor M. Durusu Tanriover (Ankara, TR)

Presentation thumbnail

Q&A and closing remarks

Professor M. Volpe (Rome, IT) Professor T. Biering-Sorensen (Copenhagen, DK) Doctor M. Durusu Tanriover (Ankara, TR)

Access the full session

Session thumbnail

Protecting beyond infection: changing the FLU paradigm for older adults

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

DANFLU-2: High-Dose vs. Standard-Dose Influenza Vaccine and Cardio-Respiratory Outcomes in Older Adults

Congress Presentation

Effect of high-dose vs. standard-dose quadrivalent influenza vaccine on death and hospitalizations in older adults with cardiovascular disease: a prespecified analysis of the DANFLU-1 study

Congress Presentation

Relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine in chronic kidney disease: a secondary analysis of the DANFLU-1 trial

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources